CCND1 and melanoma: In addition, one study reported that cyclin D1 contributes to BRAF-inhibitor resistance in cancers such as malignant melanoma [11], whereas other studies found that cyclin D1 is overexpressed in papillary thyroid carcinoma (PTC) [12, 13].